Targeting toll-like receptors on T cells as a therapeutic strategy against tumors

Red blood cell membrane-camouflaged nanoparticles loaded with AIEgen and Poly(I: C) for enhanced tumoral photodynamic-immunotherapy

(2021) Jun Dai et al.   National Science Review

DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia

(2021) L. K. Metthew Lam et al.   Science Translational Medicine

T Cell Co-stimulation and Functional Modulation by Innate Signals

(2020) Takayuki Imanishi et al.   TRENDS IN IMMUNOLOGY

Toll-like Receptors from the Perspective of Cancer Treatment

(2020) Nasir Javaid et al.   Cancers

Innate Immune Sensing by Cells of the Adaptive Immune System

(2020) Tanja Stögerer et al.   Frontiers in Immunology

A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response

(2020) Donghai Xiong et al.   Nature Communications

The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication

(2019) Xiaodong Zhuang et al.   Nature Communications

Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells

(2019) Shengmeng Di et al.   Frontiers in Oncology

The Intriguing History of Cancer Immunotherapy

(2019) Paula Dobosz et al.   Frontiers in Immunology

Red Blood Cells Homeostatically Bind Mitochondrial DNA through TLR9 to Maintain Quiescence and to Prevent Lung Injury

(2018) Meghan J. Hotz et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Toll-like receptors and their role in persistent pain

(2018) Michael J. Lacagnina et al.   PHARMACOLOGY & THERAPEUTICS

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia

(2018) Fiona C. Brown et al.   Cancer Discovery

Costimulation through TLR2 Drives Polyfunctional CD8+ T Cell Responses

(2018) Fiamma Salerno et al.   JOURNAL OF IMMUNOLOGY

Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists

(2018) Matthew D. Morin et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

(2018) Gijs G. Zom et al.   Journal for ImmunoTherapy of Cancer

Naive CD4+T Cells Carrying a TLR2 Agonist Overcome TGF-β–Mediated Tumor Immune Evasion

(2017) Mohsen Ibrahim et al.   JOURNAL OF IMMUNOLOGY

The future of personalised radiotherapy for head and neck cancer

(2017) Jimmy J Caudell et al.   LANCET ONCOLOGY

Two-step enhanced cancer immunotherapy with engineeredSalmonella typhimuriumsecreting heterologous flagellin

(2017) Jin Hai Zheng et al.   Science Translational Medicine

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

(2017) Huju Chi et al.   Frontiers in Pharmacology

Oral delivery of tumor microparticle vaccines activates NOD2 signaling pathway in ileac epithelium rendering potent antitumor T cell immunity

(2017) Wenqian Dong et al.   OncoImmunology

Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma

(2016) Fei Li et al.   CELL RESEARCH

Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+T-cell axis

(2016) Craig M. Brackett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

(2016) Elizabeth I. Buchbinder et al.   Journal for ImmunoTherapy of Cancer

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia

(2015) Nianxi Zhao et al.   BIOMATERIALS

Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo

(2015) Misako Matsumoto et al.   Nature Communications

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

(2015) R. Houot et al.   Cancer Immunology Research

Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells

(2015) Sabina Kaczanowska et al.   OncoImmunology

TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer

(2014) S. Chatterjee et al.   CANCER RESEARCH

TLR agonists: our best frenemy in cancer immunotherapy

(2013) Sabina Kaczanowska et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Toll-like receptor regulation of effector T lymphocyte function

(2013) Joseph M. Reynolds et al.   TRENDS IN IMMUNOLOGY

Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model

(2013) Chung Truong Nguyen et al.   VACCINE

Toll-Like Receptor Signaling

(2013) K.-H. Lim et al.   Cold Spring Harbor Perspectives in Biology

Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans

(2012) Atsuo Ochi et al.   JOURNAL OF CLINICAL INVESTIGATION

Anticancer function of polyinosinic-polycytidylic acid

(2011) Yu-sheng Cheng et al.   CANCER BIOLOGY & THERAPY

TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

(2011) Y. Zhang et al.   JOURNAL OF IMMUNOLOGY

Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor Antigens

(2010) D. Geng et al.   CANCER RESEARCH

Modulation of immune responses through direct activation of Toll-like receptors to T cells

(2010) G. Liu et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance

(2010) Julien Cherfils-Vicini et al.   JOURNAL OF CLINICAL INVESTIGATION

Flagellin as an Adjuvant: Cellular Mechanisms and Potential

(2010) S. B. Mizel et al.   JOURNAL OF IMMUNOLOGY

TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage

(2010) F A Carvalho et al.   Mucosal Immunology

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program

(2009) Oxana G. Palesh et al.   JOURNAL OF CLINICAL ONCOLOGY

The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate

(2009) K De Luca et al.   LEUKEMIA

Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity

(2008) Nicole Asprodites et al.   FASEB JOURNAL

Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod

(2008) Jianzhong Zhu et al.   MOLECULAR IMMUNOLOGY

An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models

(2008) L. G. Burdelya et al.   SCIENCE

The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice

(2008) Mohamed L. Salem et al.   VACCINE